Kinomera Biosciences Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 28-07-2024
- Paid Up Capital ₹ 0.01 Cr
as on 28-07-2024
- Company Age 4 years 10 months
- Last Filing with ROC 31 Mar 2023
- Revenue 34.79%
FY 2023
- Profit 220.75%
FY 2023
- Ebitda 310.07%
FY 2023
- Net Worth 2.95%
FY 2023
- Total Assets 3.63%
FY 2023
About Kinomera Biosciences
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 0.01 Cr, as per the Ministry of Corporate Affairs (MCA) records.
Venkatesh Ramakrishnan, Kannan Damodharan, and Jayshree Narkar serve as directors at the Company.
- CIN/LLPIN
U85300MH2019PTC332531
- Company No.
332531
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kinomera Biosciences?
Board Members(3)
Financial Performance and Corporate Structure Insights of Kinomera Biosciences.
Kinomera Biosciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 34.79% increase. The company also saw a substantial improvement in profitability, with a 220.75% increase in profit. The company's net worth moved up by a moderate rise of 2.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kinomera Biosciences?
In 2023, Kinomera Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kinomera Biosciences?
Kinomera Biosciences has a workforce of 14 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kinomera Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kinomera Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
